FCGR2A and neoplasm: To address the in vivo anti-tumor potential of CD32-CR T cells, three groups of CB17-SCID mice were injected subcutaneously with 1 × 106 MDA-MB-468 cells alone, with panitumumab (150 μg) or with 0.6 × 106 CD32-CR T cells.